Groprinosin, tablets 500 mg 30 pcs

Name: Groprinosin, tablets 500 mg 30 pcs
SKU: 223396
Availability: InStock

€23.40

EAN: 5997001307175 SKU: 223396 Categories: Immune system, Immunostimulants, Medicine

Description

Pharmacotherapeutic group: Immunostimulant
ATX code: J05AX05

Pharmacodynamics

Inosin pranobex is a synthetic purine derivative and is a complex containing inosin and N,N-dimethylamino-2-propanol in a molar ratio of 1:3. It has immunostimulating activity and nonspecific antiviral action. The effectiveness of the complex is determined by the presence of inosin, the second component increases its availability to lymphocytes.

It restores lymphocyte functions in immunosuppression, increases blastogenesis in monocyte population, stimulates membrane receptor expression on the surface of T-helpers, prevents decrease in lymphocyte activity under glucocorticosteroids influence, normalizes thymidine induction into lymphocytes. Inosin pranobex stimulates the activity of T-lymphocytes and natural killer cells, T-suppressor and T-helper functions, increases immunoglobulin G (Ig G), interferon-gamma, interleukins IL-1 and IL-2 production, decreases anti-inflammatory cytokines – IL-4 and IL-10, potentiates neutrophils, monocytes and macrophages chemotaxis.

The preparation shows antiviral activity in vivo against herpes simplex virus, cytomegalovirus, measles virus, human T-cell lymphoma virus (type III), polioviruses, influenza A and B viruses, human enterocytopathogenic virus (HEV), encephalomyocarditis and horse encephalitis viruses. The mechanism of antiviral action of Pranobex inosine is associated with inhibition of viral RNA and dihydropteroat synthetase involved in replication of some viruses, it enhances the suppressed viral mRNA synthesis of lymphocytes, which is accompanied by reduction of viral RNA synthesis and translation of viral proteins, increases production of alpha and gamma interferons by lymphocytes having antiviral properties. In combination treatment it increases the effect of interferon-alpha, acyclovir and zidovudine.

Pharmacokinetics

After oral administration the drug is well absorbed from the gastrointestinal tract (GIT). Maximum concentration of ingredients in blood plasma is determined after 1-2 hours. It is rapidly metabolized and excreted through the kidneys. It is metabolized similarly to endogenous purine nucleotides with formation of uric acid. N,N-dimethylamino-2-propanol is metabolized to N-oxide, and 4-acetamidobenzoate to o-acylglucuronide. No cumulation of the drug in the body has been detected. The elimination half-life (T1/2) is 3.5 h for N,N-dimethylamino-2-propanol and 50 min for 4-acetamidobenzoate. The drug and its metabolites are eliminated from the body by the kidneys within 24-48 hours.

Indications
Indications

Active ingredient
Active ingredient

Composition
Composition
1 tablet contains:
The active ingredient:inosine pranobex 500 mg.
Excipients: potato starch, povidone K 25, magnesium stearate.

How to take, the dosage
How to take, the dosage
The tablets are taken orally, after eating, with a small amount of water. The drug is taken at regular intervals (8 or 6 hours) 3-4 times a day.
Recommended doses and routes of administration:
Adults: 6 to 8 tablets daily, divided into 3 to 4 doses.
Children 3 years and older (body weight over 15-20 kg): 50 mg/kg body weight (1/2 tablet per 5 kg body weight) per day, divided into 3-4 doses.
In both adults and children, in severe infectious diseases, the dose can be increased individually up to 100 mg/kg body weight per day, divided into 4-6 doses. The maximum daily dose in adults is 3-4 g per day, the maximum daily dose in children aged 3 years and older is 50 mg/kg per day.
Durationof treatment
In acute cases: treatment usually lasts 5 to 14 days. After symptoms have disappeared, treatment should be continued for 1 to 2 days or longer, depending on the indication. If necessary, the duration of treatment may be increased individually under the supervision of a physician.
In chronic relapsing diseases: treatment in adults and children is carried out in courses of 5-10 days at intervals of 8 days. The duration of maintenance treatment can be up to 30 days, and the dose can be reduced to 500-1000 mg/day.
Herpetic infections, treatment continues for 5-10 days until symptoms disappear. To reduce the number of relapses in the asymptomatic period, the drug is prescribed 500 mg twice daily for 30 days.
Papillomavirus infections: As monotherapy the drug is prescribed for 14-28 days in a dose of 1000 mg 3 times a day for adults, and for children – 250 mg (1/2 tablet) per 5 kg of body weight 3-4 times a day.
Recurrent acute condyloma: as monotherapy or in combination with surgical treatment the drug is prescribed for adults in a dose of 1000 mg 3 times a day, for children – in a dose of 250 mg per 5 kg of body weight in 3-4 doses. Three courses of 14-28 days with an interval of 1 month are carried out.
Cervical dysplasia associated with human papillomavirus: 2-3 courses of 1000 mg 3 times a day for 10 days with an interval of 10-14 days.
Patient Special Groups
Use in elderly patients (over 65 years old)
Patient special groups
There is no need to adjust the dose, the drug is used in the same way as in middle-aged patients. It should be taken into account that elderly patients are more likely to have increased uric acid concentrations in serum and urine than patients of middle age.
Patients with renal and hepatic insufficiency
Monitoring of uric acid in serum and urine should be performed every 2 weeks during treatment with GroprinosinÂ®. Control of liver enzymes activity is recommended every 4 weeks in case of long-term treatment with the drug.

Interaction
Interaction
Immunosuppressants weaken the immunostimulatory effect of inosin pranobex.
Inosin pranobex should be used with caution in patients taking simultaneously xanthine oxidase inhibitors (allopurinol) or drugs that can block the tubular secretion of uric acid, such as “loop” diuretics (furosemide, thorasemide, etacrynic acid), since this may lead to increased uric acid serum concentration.
The co-administration of inosin pranobex with zidovudine leads to an increase in the plasma concentration of zidovudine and prolongs its half-life. Thus, when co-administering inosin pranobex with zidovudine it may be necessary to adjust the dose of zidovudine.

Special Instructions
Special Instructions

Synopsis
Synopsis

Contraindications
Contraindications
– Hypersensitivity to pranobex inosine and other components of the drug. Gout.
– Urinary stone disease.
– Chronic renal insufficiency.
– Children under 3 years of age (body weight up to 15-20 kg).
– Arrhythmias.
– Pregnancy and the period of breastfeeding.
With caution
. Caution should be used with xanthine oxidase inhibitors, diuretics, zidovudine, acute hepatic failure.

Side effects
Side effects

Overdose
Overdose
In case of overdose, gastric lavage and symptomatic therapy are indicated.

Pregnancy use
Pregnancy use
The use of the drug GroprinosinÂ® during pregnancy and during breastfeeding is contraindicated, since the safety of use has not been established.

Similarities
Similarities

Additional information
Weight 0.040 kg
Shelf life
3 years. Do not use after the expiration date stated on the package.
Conditions of storage
At a temperature not exceeding 25 °C. Keep out of reach of children.
Manufacturer
Gedeon Richter Poland, Poland
Medication form
pills
Brand
Gedeon Richter Poland